Loading…
Ar-Rahman Pharm LLC was cited for marketing an unapproved new drug called "Diabetes Support" as a dietary supplement through their website and social media channels. The company made disease claims including that the product "assists in keeping blood sugar at an optimum level" and "helps to balance blood glucose levels," which violated the Federal Food, Drug, and Cosmetic Act by establishing the product's intended use as a drug without FDA approval. These claims appeared across the company's website (ar-rahmahpharm.com), Instagram, and Facebook pages, and the FDA's review in August 2021 determined the product required either drug approval or removal of all therapeutic claims to comply with regulations.